PCS in Severe Treatment Resistant Depression
Launched by UNIVERSITY OF MINNESOTA · Oct 10, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help people with severe treatment-resistant depression, which means they have not found relief from their symptoms despite trying multiple antidepressant medications. The study involves a procedure where doctors will place small electric leads on the surface of the brain in the frontal area, right behind the forehead. This technique, called bilateral subdural prefrontal cortical stimulation (PCS), uses a device similar to a pacemaker to provide intermittent electrical stimulation to the brain, aiming to reduce depressive symptoms.
To participate in this trial, individuals need to have a diagnosis of chronic depression lasting at least two years and must have tried four or more different antidepressant treatments without success. They should also be under the care of a psychiatrist and agree to participate fully in the study's evaluations. Participants will undergo a surgical procedure, but it's important to note that this is still an experimental treatment specifically for depression. If you or a loved one is struggling with severe depression and meets these criteria, this trial could be a potential option to consider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant must be able to provide written informed consent.
- • Participant has a diagnosis of chronic (greater than or equal to 2 years) depressive episode as defined by DSM V criteria
- • Participant has not had an adequate response to four or more adequate antidepressant treatments from at least two different antidepressant treatment categories in the current depressive episode according to the Antidepressant Treatment History Form (ATHF)
- • Participant must have had ECT (Electroconvulsive Therapy) or refused to undergo ECT if clinically indicated to them
- • Participant must have HRSD greater than or equal to 20 at study entry
- • Participant must be able to complete the evaluations needed for this study including the functional imaging scans and the EEG Bayesian optimization sessions
- • Participant must be under the care of a licensed psychiatrist, undergoing regular care evaluations, and inform study team of any change to care team during study participation
- • Participant must agree to allow all forms of communication between investigators and study staff and any health care provider (current or having provided service within two years of enrollment)
- • Participant must provide name and contact information for at least two people greater than or equal to 22 in age who reside within a 30 minute drive of the participant's residents and whom staff may contact as necessary during study participation
- • Participant must be enrolled in a Medicare program
- Exclusion Criteria:
- • The PCS would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the participant
- • Participant is unable to undergo required full body magnetic resonance imaging (MRI) during the clinical study
- • Participant is judged by the investigator to be acutely suicidal (e.g. within the 30 days prior to the PCS implant the participant has made a suicide attempt or gesture or has made specific plans or preparation to commit suicide or scores 21 or higher on the MSSI)
- * In addition to the acute suicidal risks mentioned above, participant meets any of the following:
- • 1. Has made a suicide attempt within the previous 12 months that required medical treatment
- • 2. Has made greater than or equal to two suicide attempts in the past 12 months
- • 3. Has a clear-cut plan for suicide that states that she/he cannot guarantee that she/he will call her/his regular psychiatrist or the Investigator if the impulse to implement the plan becomes substantial during the study
- • 4. Is likely to attempt suicide within the next six months, in the Investigator's opinion
- • Participant has a history of schizophrenia, schizoaffective disorder, or other psychotic disorder, or a current major depressive episode that includes psychotic features (commonly referred to as psychotic depression) according to the DSM V criteria
- • Participant with a diagnosis of dementia with a Mini-Mental State Exam (MMSE) less than or equal to 23
- • Participant with a positive urine pregnancy test
- • Participant with a positive urine drug screen
- • Participant with DBS (Deep Brain Stimulator)
- • Participant with VNS (Vagus Nerve Stimulator) if the device was active in the last 6 months prior to study enrollment
- • Participant with history of seizures
- • Participant determined by surgical safety committee to have cerebral atrophy, neurodegenerative or neurovascular disease due to age or medical condition that would prohibit optimal surgical safety, per clinical MRI
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Ziad Nahas, MD
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials